Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Recruiting in Palo Alto (17 mi)

+12 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Canadian Paediatric Society

No Placebo Group

Trial Summary

What is the purpose of this trial?

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

Research Team

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria:Neisseria meningitidis isolated or detected by PCR from a normally sterile body site or fluid, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy -

Treatment Details

Interventions

Surveillance (Other)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Persons of all agesExperimental Treatment1 Intervention

Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy

Find a Clinic Near You

Who Is Running the Clinical Trial?

Canadian Paediatric Society

Lead Sponsor

Trials

Recruited

3,600+

Pfizer

Industry Sponsor

Trials

4,712

Recruited

50,980,000+

Known For

Vaccine Innovations

Top Products

**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)